Patents by Inventor Bibia Heidmann

Bibia Heidmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline form of N-[1-(5-cyano-pyridin-2-ylmethyl)-1 H-pyrazol-3-yl]-2- [4-(1-trifluoromethyl-cyclopropyl)-phenyl-acetamide
    Patent number: 11555025
    Abstract: The present invention relates to crystalline forms of N-[1-(5-cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, pharmaceutical compositions comprising said crystalline forms and their use as T-type calcium channel blockers in the treatment or prevention of diseases or disorders where T-type calcium channels are involved.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: January 17, 2023
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Bibia Heidmann, Markus Von Raumer
  • CRYSTALLINE FORM OF N-[1-(5-CYANO-PYRIDIN-2-YLMETHYL)-1 H-PYRAZOL-3-YL]-2-[4-(1-TRIFLUO-ROMETHYL-CYCLOPROPYL)-PHENYL]-ACETAMIDE
    Publication number: 20210300894
    Abstract: The present invention relates to crystalline forms of N-[1-(5-cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, pharmaceutical compositions comprising said crystalline forms and their use as T-type calcium channel blockers in the treatment or prevention of diseases or disorders where T-type calcium channels are involved.
    Type: Application
    Filed: June 11, 2021
    Publication date: September 30, 2021
    Inventors: Bibia HEIDMANN, Markus VON RAUMER
  • Crystalline form of N-[1-(5-cyano-pyridin-2- ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
    Patent number: 11059803
    Abstract: The present invention relates to crystalline forms of N-[1-(5-cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, pharmaceutical compositions comprising said crystalline forms and their use as T-type calcium channel blockers in the treatment or prevention of diseases or disorders where T-type calcium channels are involved.
    Type: Grant
    Filed: July 4, 2018
    Date of Patent: July 13, 2021
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Bibia Heidmann, Markus Von Raumer
  • Benzimidazole-proline derivatives
    Patent number: 11040966
    Abstract: The present invention relates to compounds of the formula (II) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: June 22, 2021
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi Williams
  • CRYSTALLINE FORM OF N-[1-(5-CYANO-PYRIDIN-2-YLMETHYL)-1 H-PYRAZOL-3-YL]-2-[4-(1-TRIFLUO-ROMETHYL-CYCLOPROPYL)-PHENYL]-ACETAMIDE
    Publication number: 20200165221
    Abstract: The present invention relates to crystalline forms of N-[1-(5-cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, pharmaceutical compositions comprising said crystalline forms and their use as T-type calcium channel blockers in the treatment or prevention of diseases or disorders where T-type calcium channels are involved.
    Type: Application
    Filed: July 4, 2018
    Publication date: May 28, 2020
    Inventors: Bibia HEIDMANN, Markus VON RAUMER
  • BENZIMIDAZOLE-PROLINE DERIVATIVES
    Publication number: 20190263797
    Abstract: The present invention relates to compounds of the formula (II) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.
    Type: Application
    Filed: May 7, 2019
    Publication date: August 29, 2019
    Applicant: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph BOSS, Christine BROTSCHI, Markus GUDE, Bibia HEIDMANN, Thierry SIFFERLEN, Jodi Williams
  • Benzimidazole-proline derivatives
    Patent number: 10329287
    Abstract: The present invention relates to compounds of the formula (II) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: June 25, 2019
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams
  • Triazole compounds as T-type calcium channel blockers
    Patent number: 10246426
    Abstract: The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: April 2, 2019
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Olivier Bezencon, John Gatfield, Bibia Heidmann, Romain Siegrist, Simon Stamm
  • Pyrazole compounds and their use as T-type calcium channel blockers
    Patent number: 10065929
    Abstract: The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: September 4, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Romain Siegrist, Bibia Heidmann, Simon Stamm, John Gatfield, Olivier Bezencon
  • TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS
    Publication number: 20180230109
    Abstract: The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.
    Type: Application
    Filed: September 14, 2015
    Publication date: August 16, 2018
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Olivier BEZENCON, John GATFIELD, Bibia HEIDMANN, Romain SIEGRIST, Simon STAMM
  • Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
    Patent number: 10023560
    Abstract: The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, pharmaceutical compositions containing said crystalline form, and its use as medicament, especially as orexin receptor antagonist.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: July 17, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Markus Von Raumer, Jodi T. Williams
  • PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS
    Publication number: 20180105496
    Abstract: The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.
    Type: Application
    Filed: December 19, 2017
    Publication date: April 19, 2018
    Applicant: IDORSIA PHARMACEUTICALS LTD
    Inventors: Romain SIEGRIST, Bibia HEIDMANN, Simon STAMM, John GATFIELD, Olivier BEZENCON
  • Pyrazole compounds and their use as T-type calcium channel blockers
    Patent number: 9932314
    Abstract: The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: April 3, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Romain Siegrist, Bibia Heidmann, Simon Stamm, John Gatfield, Olivier Bezencon
  • Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
    Patent number: 9914720
    Abstract: The invention relates to crystalline forms of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone, processes for the preparation thereof, pharmaceutical compositions containing such crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as orexin receptor antagonists.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: March 13, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Markus Von Raumer, Jodi T. Williams
  • Use of benzimidazole-proline derivatives
    Patent number: 9914721
    Abstract: The present invention relates to compounds of the formula (I) wherein Ar1 and Ar2 are as described in the description and to their use as pharmaceuticals for the treatment of sundown syndrome. The invention also relates to the preparation of such compounds and of pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: March 13, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Catherine Roch, Christine Brotschi, Markus Gude, Bibia Heidmann, Francois Jenck, Thierry Sifferlen, Michel Steiner, Jodi T. Williams
  • CRYSTALLINE SALT FORM OF (S)-(2-(6-CHLORO-7-METHYL-1H-BENZO[D]IMIDAZOL-2-YL)-2-METHYLPYRROLIDIN-1-YL)(5-METHOXY-2-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE AS OREXIN RECEPTOR ANTAGONIST
    Publication number: 20180002317
    Abstract: The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, pharmaceutical compositions containing said crystalline form, and its use as medicament, especially as orexin receptor antagonist.
    Type: Application
    Filed: September 12, 2017
    Publication date: January 4, 2018
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Christoph BOSS, Christine BROTSCHI, Markus GUDE, Bibia HEIDMANN, Thierry SIFFERLEN, Markus VON RAUMER, Jodi T. WILLIAMS
  • BENZIMIDAZOLE-PROLINE DERIVATIVES
    Publication number: 20170305897
    Abstract: The present invention relates to compounds of the formula (II) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.
    Type: Application
    Filed: July 7, 2017
    Publication date: October 26, 2017
    Applicant: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph BOSS, Christine BROTSCHI, Markus GUDE, Bibia HEIDMANN, Thierry SIFFERLEN, Jodi T. Williams
  • Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
    Patent number: 9790208
    Abstract: The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, pharmaceutical compositions containing said crystalline form, and its use as medicament, especially as orexin receptor antagonist.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: October 17, 2017
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Markus Von Raumer, Jodi T. Williams
  • Benzimidazole-proline derivatives
    Patent number: 9732075
    Abstract: The present invention relates to compounds of the formula (I) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: August 15, 2017
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi Williams
  • PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS
    Publication number: 20170096399
    Abstract: The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.
    Type: Application
    Filed: June 2, 2015
    Publication date: April 6, 2017
    Inventors: Romain SIEGRIST, Bibia HEIDMANN, Simon STAMM, John GATFIELD, Olivier BEZENCON